Belimumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Belimumab. Educational only — not medical advice.
Labeled uses
BENLYSTA is indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • Active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation.
Source: FDA labeling via NIH DailyMed (set 2fa3c528…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.